Pharming Group N.V.

Pre-Annual General Meeting Information • Jun 7, 2007

PHARMING'S ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD IN LEIDEN ON MAY 23, 2007

Leiden, The Netherlands, March 27, 2007. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) announced today that the Company's Annual General Meeting of Shareholders (AGM) will be held at the Pharming headquarters in Leiden on May 23, 2007 commencing at 15.00 pm CET.

Pharming intends to publish a notice in the Financieele Dagblad and the Euronext Daily Official List (Officiële Prijscourant) of May 8, 2007. All documentation relating to the AGM will be available on Pharming's website as of that date.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker (NL) Rein Strijker (NL) Investor Voice Pharming Group NV T: +31 (0)6 537 499 59 T: +31 (0)7 5247 431 T: +31 (0)71 52 47 431